Loading viewer...
investor_presentation
Format: PDF investor_presentation
MorphoSys presented its strategic oncology focus and pipeline, including Monjuvi (tafasitamab) for relapsed/refractory DLBCL and investigational programs in solid tumors, lymphomas, and myelofibrosis. The company highlighted strong cash runway extending into 2025 and outlined ambitions to redefine cancer treatment through clinical development and regulatory expansion.
investor_presentation
25 Pages
Totvs
Shriram Transport Finance Company Investor Presentation — January 2018
investor_presentationinvestor_presentation
19 Pages
Shriram Transport Finance Company